JP2006528637A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006528637A5 JP2006528637A5 JP2006521272A JP2006521272A JP2006528637A5 JP 2006528637 A5 JP2006528637 A5 JP 2006528637A5 JP 2006521272 A JP2006521272 A JP 2006521272A JP 2006521272 A JP2006521272 A JP 2006521272A JP 2006528637 A5 JP2006528637 A5 JP 2006528637A5
- Authority
- JP
- Japan
- Prior art keywords
- optionally substituted
- heterocyclyl
- alkyl
- heteroaryl
- cycloalkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000623 heterocyclic group Chemical group 0.000 claims 131
- 125000001072 heteroaryl group Chemical group 0.000 claims 124
- 229910052739 hydrogen Inorganic materials 0.000 claims 95
- 239000001257 hydrogen Substances 0.000 claims 95
- 125000003710 aryl alkyl group Chemical group 0.000 claims 88
- 125000000547 substituted alkyl group Chemical group 0.000 claims 81
- 125000004475 heteroaralkyl group Chemical group 0.000 claims 78
- 125000005346 substituted cycloalkyl group Chemical group 0.000 claims 76
- 150000002431 hydrogen Chemical class 0.000 claims 70
- 150000001875 compounds Chemical class 0.000 claims 63
- 125000003107 substituted aryl group Chemical group 0.000 claims 59
- 125000005017 substituted alkenyl group Chemical group 0.000 claims 51
- 125000004426 substituted alkynyl group Chemical group 0.000 claims 50
- 125000005843 halogen group Chemical group 0.000 claims 48
- -1 R 21 Chemical compound 0.000 claims 40
- 125000000217 alkyl group Chemical group 0.000 claims 39
- 229910052799 carbon Inorganic materials 0.000 claims 38
- 125000000753 cycloalkyl group Chemical group 0.000 claims 37
- 125000003118 aryl group Chemical group 0.000 claims 36
- 125000003342 alkenyl group Chemical group 0.000 claims 33
- 150000001721 carbon Chemical group 0.000 claims 33
- 125000000392 cycloalkenyl group Chemical group 0.000 claims 33
- 229910052757 nitrogen Inorganic materials 0.000 claims 26
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 26
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 24
- 125000000304 alkynyl group Chemical group 0.000 claims 23
- 125000004415 heterocyclylalkyl group Chemical group 0.000 claims 20
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims 13
- WMFYOYKPJLRMJI-UHFFFAOYSA-N Lercanidipine hydrochloride Chemical compound Cl.COC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)(C)CN(C)CCC(C=2C=CC=CC=2)C=2C=CC=CC=2)C1C1=CC=CC([N+]([O-])=O)=C1 WMFYOYKPJLRMJI-UHFFFAOYSA-N 0.000 claims 12
- 125000001188 haloalkyl group Chemical group 0.000 claims 12
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims 11
- 125000004043 oxo group Chemical group O=* 0.000 claims 11
- 125000000464 thioxo group Chemical group S=* 0.000 claims 11
- 125000004429 atom Chemical group 0.000 claims 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 10
- UUEVFMOUBSLVJW-UHFFFAOYSA-N oxo-[[1-[2-[2-[2-[4-(oxoazaniumylmethylidene)pyridin-1-yl]ethoxy]ethoxy]ethyl]pyridin-4-ylidene]methyl]azanium;dibromide Chemical compound [Br-].[Br-].C1=CC(=C[NH+]=O)C=CN1CCOCCOCCN1C=CC(=C[NH+]=O)C=C1 UUEVFMOUBSLVJW-UHFFFAOYSA-N 0.000 claims 9
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 8
- 239000000203 mixture Substances 0.000 claims 7
- 229910052717 sulfur Inorganic materials 0.000 claims 7
- 125000001118 alkylidene group Chemical group 0.000 claims 6
- 201000010099 disease Diseases 0.000 claims 6
- 125000004446 heteroarylalkyl group Chemical group 0.000 claims 6
- 125000002462 isocyano group Chemical group *[N+]#[C-] 0.000 claims 6
- DYMRYCZRMAHYKE-UHFFFAOYSA-N n-diazonitramide Chemical compound [O-][N+](=O)N=[N+]=[N-] DYMRYCZRMAHYKE-UHFFFAOYSA-N 0.000 claims 6
- 229910052760 oxygen Inorganic materials 0.000 claims 6
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 6
- 125000002577 pseudohalo group Chemical group 0.000 claims 6
- 125000001424 substituent group Chemical group 0.000 claims 6
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 5
- 125000001841 imino group Chemical group [H]N=* 0.000 claims 5
- 150000002923 oximes Chemical class 0.000 claims 5
- 201000001320 Atherosclerosis Diseases 0.000 claims 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 4
- 230000003143 atherosclerotic effect Effects 0.000 claims 4
- 208000035475 disorder Diseases 0.000 claims 4
- 201000001421 hyperglycemia Diseases 0.000 claims 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims 4
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 claims 4
- 125000002947 alkylene group Chemical group 0.000 claims 3
- 150000007857 hydrazones Chemical class 0.000 claims 3
- 125000001624 naphthyl group Chemical group 0.000 claims 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 3
- 102100038495 Bile acid receptor Human genes 0.000 claims 2
- 208000024172 Cardiovascular disease Diseases 0.000 claims 2
- 206010008635 Cholestasis Diseases 0.000 claims 2
- 208000032928 Dyslipidaemia Diseases 0.000 claims 2
- 101000603876 Homo sapiens Bile acid receptor Proteins 0.000 claims 2
- 208000035150 Hypercholesterolemia Diseases 0.000 claims 2
- 208000031226 Hyperlipidaemia Diseases 0.000 claims 2
- 102000004877 Insulin Human genes 0.000 claims 2
- 108090001061 Insulin Proteins 0.000 claims 2
- 208000017170 Lipid metabolism disease Diseases 0.000 claims 2
- 206010049287 Lipodystrophy acquired Diseases 0.000 claims 2
- 208000008589 Obesity Diseases 0.000 claims 2
- 230000007870 cholestasis Effects 0.000 claims 2
- 231100000359 cholestasis Toxicity 0.000 claims 2
- 206010012601 diabetes mellitus Diseases 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 229940125396 insulin Drugs 0.000 claims 2
- 208000006132 lipodystrophy Diseases 0.000 claims 2
- 235000020824 obesity Nutrition 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 239000000651 prodrug Substances 0.000 claims 2
- 229940002612 prodrug Drugs 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 239000012453 solvate Substances 0.000 claims 2
- 208000024891 symptom Diseases 0.000 claims 2
- 208000011580 syndromic disease Diseases 0.000 claims 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 2
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 0 *C1(*)C(***2)=C2C(*)=C(*)N(*)C1(*)* Chemical compound *C1(*)C(***2)=C2C(*)=C(*)N(*)C1(*)* 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US48985403P | 2003-07-23 | 2003-07-23 | |
| PCT/US2004/023745 WO2005009387A2 (en) | 2003-07-23 | 2004-07-23 | Azepine derivatives as pharmaceutical agents |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2006528637A JP2006528637A (ja) | 2006-12-21 |
| JP2006528637A5 true JP2006528637A5 (enExample) | 2007-10-04 |
| JP4679517B2 JP4679517B2 (ja) | 2011-04-27 |
Family
ID=34102943
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006521272A Expired - Fee Related JP4679517B2 (ja) | 2003-07-23 | 2004-07-23 | 薬剤としてのアゼピン誘導体 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US8466143B2 (enExample) |
| EP (1) | EP1648408A4 (enExample) |
| JP (1) | JP4679517B2 (enExample) |
| KR (1) | KR20060052867A (enExample) |
| CN (1) | CN1852748A (enExample) |
| AU (1) | AU2004259009A1 (enExample) |
| BR (1) | BRPI0412262A (enExample) |
| CA (1) | CA2532798C (enExample) |
| CR (1) | CR8258A (enExample) |
| EC (1) | ECSP066392A (enExample) |
| IL (1) | IL173287A0 (enExample) |
| NO (1) | NO20060871L (enExample) |
| RU (1) | RU2006105646A (enExample) |
| WO (1) | WO2005009387A2 (enExample) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7595311B2 (en) * | 2002-05-24 | 2009-09-29 | Exelixis, Inc. | Azepinoindole derivatives as pharmaceutical agents |
| US7402680B2 (en) | 2003-09-17 | 2008-07-22 | Janssen Pharmaceutica, N.V. | Fused heterocyclic compounds |
| BRPI0608437A2 (pt) | 2005-03-14 | 2009-12-29 | Glaxo Group Ltd | derivados tiazol fundidos que possuem afinidade para o receptor histamina h3 |
| EP1963331A1 (en) * | 2005-12-15 | 2008-09-03 | Exelixis, Inc. | Azepinoindole derivatives as pharmaceutical agents |
| US20080299118A1 (en) * | 2007-06-01 | 2008-12-04 | Wyeth | FXR Agonists for the Treatment of Malignancies |
| US20080300235A1 (en) * | 2007-06-01 | 2008-12-04 | Wyeth | FXR Agonists for Reducing LOX-1 Expression |
| US20090163474A1 (en) * | 2007-10-19 | 2009-06-25 | Wyeth | FXR Agonists for the Treatment of Nonalcoholic Fatty Liver and Cholesterol Gallstone Diseases |
| US20090215748A1 (en) * | 2007-12-20 | 2009-08-27 | Wyeth | FXR agonists for treating vitamin D associated diseases |
| BRPI0919948A2 (pt) | 2008-10-31 | 2015-08-25 | Madivation Technologies Inc | Pirido[4,3-b]indois contendo porções rígidas |
| JP5551708B2 (ja) * | 2008-10-31 | 2014-07-16 | メディベイション テクノロジーズ， インコーポレイテッド | アゼピノ［４，５−ｂ］インドール化合物およびその使用方法 |
| CN101875627B (zh) * | 2009-04-30 | 2014-01-15 | 凯惠科技发展(上海)有限公司 | 一种1-烷氧羰基-2h-异吲哚衍生物及其制备方法和中间体 |
| EP2641907B1 (en) | 2009-05-22 | 2015-01-28 | AbbVie Inc. | Preparation of modulators of 5-HT receptors |
| WO2011103433A1 (en) | 2010-02-18 | 2011-08-25 | Medivation Technologies, Inc. | Pyrido[4,3-b]indole and pyrido[3,4-b]indole derivatives and methods of use |
| US9193728B2 (en) | 2010-02-18 | 2015-11-24 | Medivation Technologies, Inc. | Fused tetracyclic pyrido [4,3-B] indole and pyrido [3,4-B] indole derivatives and methods of use |
| US9040519B2 (en) | 2010-02-18 | 2015-05-26 | Medivation Technologies, Inc. | Fused tetracyclic pyrido [4,3-B] indole and pyrido [3,4-B] indole derivatives and methods of use |
| BR112012030534A2 (pt) * | 2010-05-21 | 2015-09-29 | Abbott Gmbh & Co Kg | moduladores de receptores 5-ht e métodos de uso dos mesmos |
| WO2012112965A1 (en) * | 2011-02-18 | 2012-08-23 | Medivation Technologies, Inc. | Compounds and methods of treating diabetes |
| EP2675459A4 (en) | 2011-02-18 | 2014-08-06 | Medivation Technologies Inc | COMPOUNDS AND METHOD FOR THE TREATMENT OF DIABETES |
| WO2014031165A1 (en) * | 2012-08-22 | 2014-02-27 | Medivation Technologies, Inc. | Compounds and methods of treating diabetes |
| SG11201703953WA (en) * | 2014-11-21 | 2017-06-29 | Akarna Therapeutics Ltd | Fused bicyclic compounds for the treatment of disease |
| MX369623B (es) | 2014-12-22 | 2019-11-14 | Akarna Therapeutics Ltd | Compuestos biciclicos fusionados para el tratamiento de enfermedades. |
| TWI698430B (zh) * | 2015-02-13 | 2020-07-11 | 南北兄弟藥業投資有限公司 | 三環化合物及其在藥物中的應用 |
| HK1249756A1 (zh) * | 2015-03-26 | 2018-11-09 | Akarna Therapeutics, Ltd. | 用於治疗疾病的稠合双环化合物 |
| WO2017143134A1 (en) * | 2016-02-19 | 2017-08-24 | Alios Biopharma, Inc. | Fxr modulators and methods of their use |
| EP3463372A4 (en) * | 2016-05-25 | 2019-11-13 | Akarna Therapeutics, Ltd. | CONDENSED BICYCLIC COMPOUNDS FOR THE TREATMENT OF DISEASES |
| BR112018073460A2 (pt) * | 2016-05-25 | 2019-07-09 | Akarna Therapeutics Ltd | terapias combinadas usando moduladores do receptor farnesoide x (fxr) |
| CN111542319A (zh) * | 2017-06-02 | 2020-08-14 | 阿卡纳治疗学有限公司 | 稠合的双环化合物 |
| CN112312909B (zh) | 2018-01-26 | 2024-07-02 | 埃克塞里艾克西斯公司 | 用于治疗激酶依赖性病症的化合物 |
| US11673897B2 (en) | 2018-01-26 | 2023-06-13 | Exelixis, Inc. | Compounds for the treatment of kinase-dependent disorders |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GR35044B (el) * | 1966-05-10 | 1968-07-31 | The Upjohn Company | Μεθοδος παρασκευης οργανικων ενωσεων. |
| US4362739A (en) * | 1981-05-04 | 1982-12-07 | S.A. Omnichem | Pyrrolo(2,3-d)carbazole derivatives, compositions and use |
| IL101851A (en) * | 1991-06-13 | 1996-05-14 | Janssen Pharmaceutica Nv | 10-(4-piperidinyl- and piperidinylidene)-imidazo [1,2-a] (pyrrolo thieno or furano) [2,3] azepine derivatives their preparation and pharmaceutical compositions containing them and certain novel intermediates therefor |
| JPH09221475A (ja) * | 1996-02-13 | 1997-08-26 | Yamanouchi Pharmaceut Co Ltd | 新規なオキシム誘導体 |
| WO1999006410A1 (en) * | 1997-08-04 | 1999-02-11 | Amgen Inc. | Hydroxamic acid substituted fused heterocyclic metalloproteinase inhibitors |
| AR024576A1 (es) | 1999-06-18 | 2002-10-16 | Univ Washington | Composiciones y metodos para aumentar el flujo de salida de colesterol y aumentar la hdl usando la proteina abc1 transportadora del cassette que une elatp |
| FR2796070B1 (fr) * | 1999-07-06 | 2003-02-21 | Lipha | Derives de benzodiazepines utilisables dans le traitement de dyslipidemies, de l'atherosclerose et du diabete, compositions pharmaceutiques les contenant et procedes de preparation |
| MY122278A (en) * | 1999-07-19 | 2006-04-29 | Upjohn Co | 1,2,3,4,5,6-hexahydroazepino[4,5-b]indoles containing arylsulfones at the 9-position |
| US20020013334A1 (en) * | 2000-06-15 | 2002-01-31 | Robl Jeffrey A. | HMG-CoA reductase inhibitors and method |
| US7595311B2 (en) * | 2002-05-24 | 2009-09-29 | Exelixis, Inc. | Azepinoindole derivatives as pharmaceutical agents |
| TWI329111B (en) | 2002-05-24 | 2010-08-21 | X Ceptor Therapeutics Inc | Azepinoindole and pyridoindole derivatives as pharmaceutical agents |
| EP1963331A1 (en) * | 2005-12-15 | 2008-09-03 | Exelixis, Inc. | Azepinoindole derivatives as pharmaceutical agents |
-
2004
- 2004-07-23 WO PCT/US2004/023745 patent/WO2005009387A2/en not_active Ceased
- 2004-07-23 EP EP04779004A patent/EP1648408A4/en not_active Withdrawn
- 2004-07-23 CN CNA2004800270768A patent/CN1852748A/zh active Pending
- 2004-07-23 KR KR1020067001566A patent/KR20060052867A/ko not_active Withdrawn
- 2004-07-23 RU RU2006105646/04A patent/RU2006105646A/ru not_active Application Discontinuation
- 2004-07-23 US US10/565,702 patent/US8466143B2/en active Active
- 2004-07-23 JP JP2006521272A patent/JP4679517B2/ja not_active Expired - Fee Related
- 2004-07-23 AU AU2004259009A patent/AU2004259009A1/en not_active Abandoned
- 2004-07-23 BR BRPI0412262-3A patent/BRPI0412262A/pt not_active IP Right Cessation
- 2004-07-23 CA CA2532798A patent/CA2532798C/en not_active Expired - Fee Related
-
2006
- 2006-01-22 IL IL173287A patent/IL173287A0/en unknown
- 2006-02-22 NO NO20060871A patent/NO20060871L/no not_active Application Discontinuation
- 2006-02-23 EC EC2006006392A patent/ECSP066392A/es unknown
- 2006-02-23 CR CR8258A patent/CR8258A/es not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2006528637A5 (enExample) | ||
| RU2006105646A (ru) | Производные азепина в качестве фармацевтических агентов | |
| JP6460991B2 (ja) | 抗菌剤として使用するための三環式ジャイレース阻害剤 | |
| US10435415B2 (en) | Substituted tetrahydrocarbazole and carbazole carboxamide compounds | |
| US9714234B2 (en) | Carbazole carboxamide compounds | |
| JP2009536189A5 (enExample) | ||
| JP2023027102A (ja) | オルトミクソウイルス感染症を治療するのに有用な縮合三環式ピリダジノン化合物 | |
| AU2007223342A1 (en) | Pyrrolotriazine aniline prodrug compounds useful as kinase inhibitors | |
| JP2005509038A5 (enExample) | ||
| WO2017031325A1 (en) | Oxadiazine compounds and methods of use thereof | |
| US10023534B2 (en) | Carbazole and tetrahydrocarbazole compounds useful as inhibitors of BTK | |
| HUP0004020A2 (hu) | Triciklusos triazolo-benzazepin-származékok, eljárás a vegyületek előállítására és alkalmazásuk antiallergiás szerként | |
| KR20030005386A (ko) | 비닐-피롤리디논 세팔로스포린 유도체의 신규 제조방법 | |
| CA3137676A1 (en) | Fused heterocyclic derivatives | |
| KR20220015426A (ko) | 캡시드 조립 조절제로서의 융합 복소환 유도체 | |
| CA3136493A1 (en) | Diazepinone derivatives as capsid assembly modulators | |
| HUT66178A (en) | Pharmaceutical compositions containing 6-heterocyclyl-4-amino-1,2,2a,3,4,5-hexahydro-benz/cd/indole derivatives use fules for treating motion sickness and vomiting | |
| WO1993012120A1 (fr) | Derive de pyrazolothiazolopyrimidine | |
| CA2502488A1 (fr) | Nouveaux derives de [1,4]benzodioxino[2,3-e]isoindole substitues, leur procede de preparation et les compositions pharmaceutiques qui les contiennent | |
| OA19480A (en) | Pharmacologically active alicyclicsubstituted pyrazolo [1,5-a] pyrimidine derivatives. | |
| Domostoj | Enantiospecific total synthesis of (-)-agelastatin A and evaluation of its biological properties | |
| HK1223359B (en) | Substituted tetrahydrocarbazole and carbazole carboxamide compounds useful as kinase inhibitors | |
| JPH0127074B2 (enExample) |